Structure Therapeutics INC Form 4 insider transactions

Structure Therapeutics' Chief Scientific Officer, Lin Xichen, disposed of 12,846 ordinary shares to cover tax obligations related to a restricted share unit award.

FMR LLC, a significant 10% owner of Structure Therapeutics Inc., has disclosed a pre-planned sale of 26,310 American Depositary Shares scheduled for July 30, 2025, under a Rule 10b5-1 trading plan.

Structure Therapeutics Inc.'s Chief Medical Officer, Blas Coll Crespo, reported the acquisition of Ordinary Shares through performance-vesting restricted share units and an employee share purchase plan, alongside dispositions for tax obligations.

Structure Therapeutics Inc.'s Chief Technology Officer, Ma Yingli, reported routine share transactions including the vesting of performance-based restricted share units and shares withheld for tax obligations.

Structure Therapeutics Inc.'s Chief Scientific Officer, Lin Xichen, reported the vesting of 57,078 performance-based restricted share units and the disposition of 6,441 shares for tax obligations.

Structure Therapeutics Inc.'s Chief Financial Officer, Jun Yoon, reported recent acquisitions of performance-vesting restricted share units and dispositions for tax obligations, alongside updates to direct and indirect shareholdings.

Structure Therapeutics Inc.'s CEO and Director, Raymond C. Stevens, reported multiple transactions including the vesting of performance-based restricted share units, shares withheld for tax obligations, and an acquisition through the Employee Share Purchase Plan.

Structure Therapeutics Inc. Director Angus C. Russell was granted 42,833 share options with an exercise price of $7.37 per share, aligning his interests with shareholders.

Ted W. Love, a Director of Structure Therapeutics Inc., was granted 51,804 share options with an exercise price of $7.37 per share, vesting over 12 months.

Joanne Waldstreicher, a Director at Structure Therapeutics Inc., has been granted 51,804 share options with an exercise price of $7.37 per share, aligning her interests with the company's long-term performance.

Structure Therapeutics Inc. Director Eric Dobmeier was granted 51,804 share options with an exercise price of $7.37 per share, vesting over 12 months.

Sharon Tetlow, a Director at Structure Therapeutics Inc., was granted 51,804 stock options with an exercise price of $7.37 per share, vesting over 12 months.

Structure Therapeutics Inc. Director Daniel G. Welch was granted 51,804 share options with an exercise price of $7.37 per share, vesting over 12 months.

Chief Medical Officer of Structure Therapeutics, Blas Coll Crespo, reports acquisition and disposal of ordinary shares and derivative securities, including stock options and restricted stock units.

Ashley Hall, Chief Development Officer of Structure Therapeutics Inc., was granted stock options and restricted stock units (RSUs) on March 15, 2025.

Chief Technology Officer Ma Yingli reports acquisition of restricted stock units and stock options in Structure Therapeutics Inc.

Chief Scientific Officer Lin Xichen reports acquisition and disposal of ordinary shares and stock options in Structure Therapeutics Inc.

Jun Yoon, CFO of Structure Therapeutics, reports acquisition and disposal of ordinary shares and derivative securities, including stock options and restricted stock units.

Raymond Stevens, CEO of Structure Therapeutics, reports the acquisition of restricted stock units and stock options.

FMR LLC, along with related entities and Abigail P. Johnson, reports changes in beneficial ownership of Structure Therapeutics Inc. securities.

Ashley Hall, Chief Development Officer of Structure Therapeutics, reports acquisition of shares and options in the company.

Dr. Blas Coll Crespo, Chief Medical Officer of Structure Therapeutics Inc., reports acquisition of shares and options.

Director Angus C. Russell acquired 75,000 share options in Structure Therapeutics Inc. on August 26, 2024, according to a Form 4 filing.

Director Ted W. Love acquired 33,595 share options in Structure Therapeutics Inc. on June 25, 2024.

Director Joanne Waldstreicher acquired 37,500 share options in Structure Therapeutics Inc. on June 25, 2024.

Director Eric Dobmeier acquired 37,500 share options in Structure Therapeutics Inc. on June 25, 2024, according to a Form 4 filing.

Director Sharon Tetlow acquired 37,500 share options in Structure Therapeutics Inc. on June 25, 2024.

Director Daniel G. Welch acquired share options in Structure Therapeutics Inc. on June 25, 2024.

Raymond C. Stevens, CEO of Structure Therapeutics, executed stock options to acquire ordinary shares at prices of $0.39 and $0.48, subsequently adjusting his beneficial ownership.

Raymond C. Stevens, CEO of Structure Therapeutics Inc., converted ordinary shares into American Depositary Shares (ADS) and sold them at an average price of $52.7965.